A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E3296)

Oncology

Volumn 58, Issue 3, 2000, Pages 215-218

  Berlin, Jordan D ^a,g   Adak, Sudeshna ^b   Vaughn, David J ^c   Flinker, David ^d   Blaszkowsky, Lawrence ^e   Harris, Jules E ^f   Benson III, Al Bowen ^f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Mem Hospital of Burlington County   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY   (United States)

Author keywords

5 Fluorouracil; Gemcitabine; Pancreas cancer; Phase II trial

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG DISEASE; MALE; METASTASIS; MOTOR DYSFUNCTION; NAUSEA; NEUROTOXICITY; ONCOLOGY; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 0034029777     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012103     Document Type: Article

References (11)

1. Lionetto R, Pugliese V, Bruzzi P, Rosso R: No Standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1998;31A: 882-887.
2. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
3. Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger KA, Marnocha RM, Wilding G: A phase I study of gemcitabine, 5-fluorouracil, and leucovorin in patients with advanced, recurrent and/or metastatic solid tumors. Invest New Drugs 1999;16: 325-330.
4. Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, Pancera G, Giordani P, Giuliodori L, Pessi MA, Fusco V, Luporini G, Cellerino R, Catalano G: A combination of genicitabine and 5-fluorouracil in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1999;80:1595-1598.
5. Cortes-Funes H, Castellano D, Paz-Ares L, Gravates C, Alonso S, Hitt R, Hidalgo M: A phase I-II study of gemcitabine (GEM) plus continuous infusion (CI) 5-fluorouracil (5-FU) in patients with advanced pancreatic cancer (APC) (abstract). Proc Am Soc Clin Oncol 1998;17:265a.
6. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585-592.
7. Poplin E, Roberts J, Tombes M, Grant S, Rubin E: Leucovorin, 5-fluorouracil, and gemcitabinc: A phase I study. Invest New Drugs 1999; 17:57-61.
8. Madajewicz S, Viola M, Hentschel P, Caruso R. Fried M, Burns P: Phase 1 study of combination chemotherapy with folinic acid/5-FU/gemcitabine (abstract). Proc Am Soc Clin Oncol 1998;17:247a.
9. Schulz L, Schalhorn A, Wilmanns W, Heinemann V: Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells (abstract). Proc Am Soc Clin Oncol 1988;17: 251a.
10. Ren Q, Kao V, Grem JL: Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998;4:2811-2818.
11. Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H. Lenzi R, Abbruzzesse J: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma (abstract). Proc Am Soc Clin Oncol 1999;18:273a.